Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.
作者信息
Rimando Joseph C, Christopher Matthew J, Rettig Michael P, DiPersio John F
机构信息
Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO.
出版信息
J Clin Oncol. 2021 Feb 10;39(5):386-396. doi: 10.1200/JCO.20.01587. Epub 2021 Jan 12.
Abstract
摘要
相似文献
1
Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.髓系疾病中疾病复发的生物学：对干细胞移植后预防和治疗疾病复发策略的启示
J Clin Oncol. 2021 Feb 10;39(5):386-396. doi: 10.1200/JCO.20.01587. Epub 2021 Jan 12.
2
Treatments of disease relapse after allogeneic stem cell transplantation focusing on donor lymphocyte infusion.以供体淋巴细胞输注为重点的异基因干细胞移植后疾病复发的治疗方法。
Chin Med J (Engl). 2013 Nov;126(22):4380-8.
3
Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.急性髓系白血病异基因造血细胞移植后降低复发的策略。
Curr Hematol Malig Rep. 2013 Jun;8(2):132-40. doi: 10.1007/s11899-013-0153-6.
4
The Total Body Irradiation Schedule Affects Acute Leukemia Relapse After Matched T Cell-Depleted Hematopoietic Stem Cell Transplantation.全身照射方案对匹配的T细胞去除型造血干细胞移植后急性白血病复发的影响。
Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):832-839. doi: 10.1016/j.ijrobp.2016.07.025. Epub 2016 Jul 27.
5
The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years.谁、如何以及为什么：异基因移植治疗 60 岁以上急性髓系白血病。
Blood Rev. 2017 Nov;31(6):362-369. doi: 10.1016/j.blre.2017.07.002. Epub 2017 Jul 15.
6
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.异基因造血干细胞移植后巨细胞病毒再激活与移植后存活至第100天的急性髓系白血病患者复发风险降低相关：日本造血细胞移植学会移植相关并发症工作组
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
7
Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation.造血干细胞移植治疗急性髓系白血病。
Future Oncol. 2009 May;5(4):559-68. doi: 10.2217/fon.09.20.
8
Current strategies in immunotherapy for acute myeloid leukemia.急性髓细胞白血病的免疫治疗策略。
Immunotherapy. 2013 Jan;5(1):63-78. doi: 10.2217/imt.12.145.
9
Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis.异基因造血干细胞移植后复发的急性髓系白血病或骨髓增生异常综合征的阿扎胞苷治疗，多中心 PALG 分析。
Eur J Haematol. 2021 Jul;107(1):129-136. doi: 10.1111/ejh.13628. Epub 2021 Apr 4.
10
Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.巨细胞病毒再激活对急性髓细胞白血病患者异基因造血细胞移植后复发的保护作用受预处理方案的影响。
Biol Blood Marrow Transplant. 2014 Jan;20(1):46-52. doi: 10.1016/j.bbmt.2013.10.003. Epub 2013 Oct 10.
引用本文的文献
1
Aging and Age-Related Epigenetic Drift in the Pathogenesis of Leukemia and Lymphomas: New Therapeutic Targets.衰老和与年龄相关的表观遗传漂移在白血病和淋巴瘤发病机制中的作用：新的治疗靶点。
Cells. 2023 Sep 30;12(19):2392. doi: 10.3390/cells12192392.
2
Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.在接受异基因造血细胞移植的老年 B 细胞急性淋巴细胞白血病患者中，与年长的同胞供体相比，年轻的匹配无关供体可降低复发风险。
Transplant Cell Ther. 2023 Oct;29(10):611-618. doi: 10.1016/j.jtct.2023.07.015. Epub 2023 Jul 21.
3
Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia.供者年龄对老年急性髓系白血病患者异基因造血细胞移植结局的影响。
Transplant Cell Ther. 2023 Sep;29(9):578.e1-578.e9. doi: 10.1016/j.jtct.2023.06.020. Epub 2023 Jul 3.
4
Transplant in AML with measurable residual disease: proceed or defer?伴可测量残留病的 AML 患者的移植：进行还是推迟？
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):528-533. doi: 10.1182/hematology.2022000353.
5
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.使用基质锚定细胞因子增强 ADCC：F16IL2 和 BI 836858 治疗移植后 AML 复发的 1 期试验。
Blood Adv. 2022 Jun 28;6(12):3684-3696. doi: 10.1182/bloodadvances.2021006909.
6
Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse.多组学整合分析鉴定表观遗传调控因子 PRC2 为克服白血病免疫逃逸和复发的治疗靶点
Cancer Discov. 2022 Jun 2;12(6):1449-1461. doi: 10.1158/2159-8290.CD-21-0980.
本文引用的文献
1
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.TP53 异常与免疫浸润相关，并与 AML 中对 flotetuzumab 免疫治疗的反应相关。
Blood Adv. 2020 Oct 27;4(20):5011-5024. doi: 10.1182/bloodadvances.2020002512.
2
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.索拉非尼维持治疗伴 FLT3-ITD 急性髓系白血病行异基因造血干细胞移植患者：一项开放标签、多中心、随机 3 期临床试验。
Lancet Oncol. 2020 Sep;21(9):1201-1212. doi: 10.1016/S1470-2045(20)30455-1. Epub 2020 Aug 10.
3
Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation.吉妥珠单抗奥佐米星联合强化化疗治疗异基因造血干细胞移植后复发的急性髓系白血病。
Clin Lymphoma Myeloma Leuk. 2020 Dec;20(12):791-796. doi: 10.1016/j.clml.2020.07.001. Epub 2020 Jul 6.
4
Immunogenomic Landscape of Hematological Malignancies.血液系统恶性肿瘤的免疫基因组全景
Cancer Cell. 2020 Sep 14;38(3):380-399.e13. doi: 10.1016/j.ccell.2020.06.002. Epub 2020 Jul 9.
5
Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia.靶向组蛋白去乙酰化酶调节移植物抗宿主病和移植物抗白血病。
Int J Mol Sci. 2020 Jun 16;21(12):4281. doi: 10.3390/ijms21124281.
6
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia.免疫图谱可预测急性髓系白血病的化疗耐药性和免疫治疗反应。
Sci Transl Med. 2020 Jun 3;12(546). doi: 10.1126/scitranslmed.aaz0463.
7
Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia.急性髓系白血病中基于测序的可测量残留病检测
Front Cell Dev Biol. 2020 May 8;8:249. doi: 10.3389/fcell.2020.00249. eCollection 2020.
8
The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.基于 venetoclax 的挽救性治疗在急性髓细胞白血病造血干细胞移植后复发中的应用。
Am J Hematol. 2020 Sep;95(9):1006-1014. doi: 10.1002/ajh.25859. Epub 2020 Jun 15.
9
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.Toll样受体7/8成熟RNA转导的树突状细胞作为急性髓系白血病缓解后治疗：一项I期试验的结果
Clin Transl Immunology. 2020 Mar 3;9(3):e1117. doi: 10.1002/cti2.1117. eCollection 2020.
10
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation.异基因造血干细胞移植后纳武利尤单抗维持治疗时出现意外毒性。
Biol Blood Marrow Transplant. 2020 May;26(5):1025-1027. doi: 10.1016/j.bbmt.2020.01.021. Epub 2020 Feb 1.
Zotero 插件